天花疫苗(Bavarian Nordic A/S)(Smallpox vaccine(Bavarian Nordic A/S)) - 在研适应症：猴痘，天花，牛痘病毒感染_专利_临床

概要

基本信息

药物类型

减毒活疫苗、预防性疫苗

别名

modified vaccinia Ankara - Bavarian Nordic (MVA-BN) virus、modified vaccinia Ankara virus、Modified Vaccinia Ankara-Bavarian Nordic

+ [11]

靶点-

作用机制

免疫刺激剂

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

非在研机构-

最高研发阶段批准上市

首次获批日期

欧盟 (2013-07-31),

猴痘天花牛痘病毒感染

最高研发阶段(中国)-

特殊审评紧急使用授权 (美国)

登录后查看首次获批时间轴

关联

29

项与天花疫苗(Bavarian Nordic A/S) 相关的临床试验

NCT05513313 / Not yet recruitingN/A

Prospective Assessment of Myocarditis After Replication-Deficient Smallpox Immunization

This is a prospective observational phase IV study of a novel, replication-deficient smallpox vaccine that has been recently been approved by FDA. The purpose of this study is to determine if there are any abnormalities detected by electrocardiographic testing and/or blood tests within 35 days of receiving the second dose of smallpox vaccine either alone or co-administered with other vaccines that may/may not be suggestive of myopericarditis.

开始日期2029-03-01

申办/合作机构

Womack Army Medical Center

[+1]

NCT05745987 / Not yet recruiting临床4期IIT

SMART (Smallpox Vaccine for Mpox Post-Exposure Prophylaxis: A Cluster Randomized Controlled Trial)

A cluster randomized controlled trial to determine if smallpox vaccine reduces secondary cases and symptom severity in persons exposed to mpox.

开始日期2024-09-01

申办/合作机构

McMaster University

NCT06366672 / Recruiting早期临床1期IIT

Evaluating the Durability of the Human Immune Response to the JYNNEOS Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) Vaccine

This study is designed to evaluate the magnitude and duration of the human adaptive immune response to the JYNNEOS Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine in the blood, lung mucosa, skin and bone marrow.

开始日期2024-06-10

申办/合作机构

Washington University School of Medicine

100 项与天花疫苗(Bavarian Nordic A/S) 相关的临床结果

登录后查看更多信息

100 项与天花疫苗(Bavarian Nordic A/S) 相关的转化医学

登录后查看更多信息

100 项与天花疫苗(Bavarian Nordic A/S) 相关的专利（医药）

登录后查看更多信息

1,426

项与天花疫苗(Bavarian Nordic A/S) 相关的文献（医药）

2108-11-15·Psychiatria Danubina4区 · 医学

NON-SUICIDAL SELF-INJURY AMONG UNIVERSITY STUDENTS IN TURKEY: THE EFFECT OF GENDER AND CHILDHOOD ABUSE

4区 · 医学

Article

作者: Idig-Camuroglu, Meltem ; Gölge, Z Belma

BACKGROUND:

The purpose of this study was to explore the effect of gender and childhood abuse on non-suicidal self-injurious (NSSI) behaviors among university students in Turkey.

SUBJECTS AND METHODS:

In this study convenience sampling technique was used, the sample consisted of 1000 young adults who were from the eight universities in two big cities; Istanbul and Ankara. Besides with demographic questionnaire, Inventory of Statements about Self-Injury and Childhood Trauma Questionnaire were used.

RESULTS:

The prevalence of NSSI was 28.5% and the most prevalent three self-injurious behaviors were wound picking, banging/hitting and pinching self. There was not a gender difference in NSSI behavior frequency but in the type of behavior; males had significantly higher percentages of hitting and burning behavior. Examining the intrapsychic and interpersonal functions of NSSI, "affect regulation" and "toughness" functions were the most used ones among the participants. In terms of gender differences, "revenge" function was used by females more than males. Self-injurers had higher childhood abuse scores on sexual, physical, and emotional abuse and neglect subscales than non self-injurers, and males were significantly more abused than females.

CONCLUSIONS:

Accepting childhood abuse as an important predictor of NSSI behavior, screening and assessment of abused children and adolescents can help to prevent the onset of the behavior.

2024-12-31·Expert review of vaccines

Immunogenicity and safety of ebolavirus vaccines in healthy adults: a systematic review and meta-analysis of randomized controlled trials

Review

作者: Miao, Mingsan ; Qin, Changjiang ; Wang, Chaoyang ; Zhang, Liang ; Yin, Juntao

BACKGROUND:

This review aimed to systematically evaluate the immunogenicity and safety of the candidate Ebola virus vaccine (EVV).

METHODS:

We searched five databases for randomized controlled trials (RCTs) evaluating the effects of EVV on healthy adults. The primary outcomes were relative risk (RR) of sero-conversion or sero-response of EVV in healthy adults between the groups that received EVV and the controls.

RESULTS:

Twenty-nine RCTs (n = 23573) were included. There was a significant difference in RR of sero-conversion of EVV (RR 13.18; 95% CI 11.28-15.41; I² = 33%; P < 0.01) between the two groups. There was a significant difference in RR of adverse events (AEs) of EVV (RR 1.49; 95% CI 1.27-1.74; I² = 88%; P < 0.01), although no difference in RR of serious AE (SAE) between the two groups. Subgroup analysis showed that there was no significant difference in RR of AEs for DNAEBO, EBOV-GP, MVA, and rVSVN4CT1 vaccines, compared with controls.

CONCLUSIONS:

The DNAEBO, EBOV-GP, MVA, and rVSVN4CT1 vaccines are likely to be safe and immunogenic, tending to support the vaccination against Ebola disease. These findings should provide much-needed evidence for public health policy makers to develop preventive measures based on disease prevalence features and socio-economic conditions.

2024-03-26·The Journal of infectious diseases

Epidemiology of the 2022 Mpox Outbreak in the US Veterans Health Administration

Article

作者: Trevino, Christina ; Oda, Gina ; Schirmer, Patricia ; Holodniy, Mark ; Elbeik, Tarek ; Edson, Connor ; Lucero-Obusan, Cynthia

Abstract:

Background:

In May 2022, mpox cases were reported in nonendemic countries, including the United States. We examined mpox infections in the Veterans Health Administration (VHA).

Methods:

Mpox diagnostic and whole genome sequencing (WGS) results, demographics, risk factors, hospitalizations, exposures, deaths, and pharmacy and immunization data were obtained from VHA data sources (23 May 2022–31 May 2023).

Results:

Of 1144 Veterans tested, 251 (21.9%) were presumptive positive for nonvariola orthopoxvirus (NVO) or confirmed positive for NVO and Monkeypox virus (MPXV). Incidence rate was 7.5 per 100 000 Veterans in care, with the highest rate observed in Veterans aged 25–34 years (13.83 cases per 100 000). Higher odds of NVO or NVO/MPXV positivity was associated with male sex; non-Hispanic Black race/ethnicity; syphilis or human immunodeficiency virus (HIV) positivity; or genital/rectal sample site, whereas older age and vaccination with JYNNEOS or vaccinia (smallpox) had lower odds. Among 209 with confirmatory testing, 90.4% reported intimate contact and/or an epidemiological link, 84.5% were men who have sex with men (MSM), 24.2% received tecovirimat, and 8.1% were hospitalized with 1 death. Eighty-six sequenced samples had evaluable WGS results. All were clade IIb, representing 10 different lineages from 20 states and the District of Columbia.

Conclusions:

Mpox affected younger, MSM, non-Hispanic Black, and HIV/syphilis-positive men among US Veterans. Viral diversity was noted across geographic regions. At-risk Veterans would benefit from vaccination and risk reduction strategies for mpox and other sexually transmitted infections.

359

项与天花疫苗(Bavarian Nordic A/S) 相关的新闻（医药）

2024-09-19

·GlobeNewswire-Health Care

Bavarian Nordic Receives EMA Approval of Mpox Vaccine for Adolescents

MVA-BN approved for use against mpox and smallpox in adolescents 12-17 years of age after expedited review with EMARepresents the second EMA approval of an MVA-BN-based vaccine for a younger population COPENHAGEN, Denmark, September 19, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that the European Commission has adopted the Committee for Medicinal Products for Human Use (CHMP) recommendation for the approval of a type II variation for IMVANEX® (MVA-BN) smallpox and mpox vaccine, extending the current marketing authorization to include adolescents 12 to 17 years of age. The CHMP recommendation follows the submission last month to EMA of data from a clinical study (NCT05740982), sponsored by the U.S. National Institutes of Health’s (NIH) National Institutes of Allergy and Infectious Diseases (NIAID), in 315 adolescents 12-17 years of age and 211 adults aged 18 years and older, demonstrating non-inferiority of the immune responses as well as a similar safety profile between both age groups after vaccination with two standard doses of the MVA-BN vaccine. While this represents the first approval of MVA-BN as a smallpox/mpox vaccine for adolescents, a recombinant version of MVA-BN (Mvabea®) was approved by EMA in 2020 as part of a prime-boost vaccine regimen1 for the prevention of disease caused by Ebola virus in individuals ≥1 year of age. Clinical studies supporting this approval encompass more than 3,300 individuals across Europe, USA, and Africa including over 800 children and adolescents 1-17 years of age in Africa2. The safety profile of Mvabea in children 1-17 years of age was generally similar to that observed in adults and similar to the safety profile of MVA-BN in individuals 12 years and older. Paul Chaplin, President & CEO of Bavarian Nordic, said: “We applaud EMA for their expedited review and decision to recommend approval of MVA-BN for adolescents. This represents an important milestone in our efforts to make our vaccine available for all populations and will help improve access for some of the most vulnerable individuals mostly impacted by the ongoing mpox outbreak in Africa.” Bavarian Nordic is preparing for a clinical trial (NCT06549530) to assess the immunogenicity and safety of MVA-BN in children 2-12 years of age, aiming to further extend the indication of the vaccine into younger populations. The trial, partially funded by the Coalition for Epidemic Preparedness Innovations (CEPI), is expected to start next month. CEPI has also co-funded a clinical study (NCT05745987), led by McMaster University in Canada, to assess post-exposure vaccination with MVA-BN, i.e. if the vaccine helps reduce the risk of secondary mpox cases, or, in case of mpox infection, can reduce the severity of illness. The study will include over 1.500 participants including children in households with a laboratory-confirmed mpox infection at sites in the DRC, Uganda and Nigeria. Results of the study could provide important findings to inform vaccination strategies in areas impacted by the mpox outbreak. About the mpox vaccineMVA-BN or Modified Vaccinia Ankara-Bavarian Nordic is the only non-replicating mpox vaccine approved in the U.S., Switzerland, Singapore and Mexico (marketed as JYNNEOS®), Canada (marketed as IMVAMUNE®), and the EU/EAA and United Kingdom (marketed as IMVANEX®). Originally developed as a smallpox vaccine in collaboration with the U.S. government to ensure the supply of a smallpox vaccine for the entire population, including immunocompromised individuals who are not recommended vaccination with traditional replicating smallpox vaccines, MVA-BN has been indicated for use in the general adult population in individuals considered at risk for smallpox or mpox infection. Bavarian Nordic has been a long-term supplier of the vaccine to national stockpiles, and during the 2022-2023 mpox outbreak, the Company supported governments and supranational organizations by expanding access to the vaccine to more than 70 countries worldwide. About Bavarian NordicBavarian Nordic is a fully integrated vaccine company with a mission to protect and save lives through innovative vaccines. We are a global leader in smallpox and mpox vaccines, supplied to governments to enhance public health preparedness and have a strong portfolio of vaccines for travelers and endemic diseases. For more information visit www.bavarian-nordic.com. Forward-looking statements This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law. ContactsEurope: Rolf Sass Sørensen, Vice President Investor Relations, rss@bavarian-nordic.com, Tel: +45 61 77 47 43US: Graham Morrell, Paddock Circle Advisors, graham@paddockcircle.com, Tel: +1 781 686 9600 1 Mvabea® was licensed in 2014 to Johnson & Johnson as part of a prime-boost vaccine regimen. 2 https://www.ema.europa.eu/en/documents/assessment-report/mvabea-epar-public-assessment-report_en.pdf Attachment 2024-09-19-en

上市批准疫苗临床研究加速审批

2024-09-19

·Endpoints

BioCentriq names ex-Resilient exec as new CEO; Sanofi, AstraZeneca boost Beyfortus production

Welcome to Endpoints News ’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Cell therapy CDMO BioCentriq has appointed Syed Husain as its new CEO, who recently was the chief commercial officer at Resilience. Prior to Resilience, Husain held roles at Alcami, Emergent BioSolutions and Lonza, according to a Thursday announcement. Sanofi and AstraZeneca have secured FDA approval for a new manufacturing filling line to boost production capacity for their respiratory syncytial virus vaccine, according to a Monday release. Sanofi is already shipping 50 mg and 100 mg lots of Beyfortus to US private healthcare providers and the Centers for Disease Control and Prevention for its initiative called Vaccines for Children. Earlier this year, Sanofi warned Beyfortus would be in short supply in the first quarter 2024 and was honed in on boosting manufacturing capacity. Gavi, the Vaccine Alliance, has purchased 500,000 doses of Bavarian Nordic’s mpox vaccine for use in Africa, the consortium said Wednesday. The UK government has also purchased 150,000 doses of Bavarian Nordic’s mpox vaccine for local use. The UK is prioritizing vaccinations for men who have sex with men, healthcare workers, specialist healthcare and humanitarian workers, and those in close contact with someone infected with mpox, according to a Tuesday announcement. Lonza has opened a new facility at its site in Colmar, France, dubbed the “Innovaform Accelerator,” the company said Thursday . The new facility will develop oral and pulmonary drug delivery systems. Thermo Fisher Scientific’s clinical research and analytical arm, PPD, is expanding its laboratory services with a new 29,000-square-foot bioanalytical lab. It will be located at the GoCo Health Innovation City in Gothenburg, Sweden. The new lab will cover small and large molecules as well as biomarkers, the company said Wednesday. Cell therapy CDMO Kincell Bio has secured a multi-year partnership with an unnamed customer, the manufacturer said Monday. Under the deal, Kincell will make the client’s cell therapy for degenerative disease at its facility in Gainesville, FL. CDMO Recipharm has expanded its oral solid development site in Zwickau, Germany, by adding three manufacturing suites for blending, tableting and filling capsules. The expansion will be operational by the first quarter of 2025, the company said Monday. Richter BioLogics has opened a new manufacturing factory in Bovenau, Germany, according to a Monday release. The 10,000-square-meter facility houses clinical and commercial manufacturing of protein and DNA-based therapies, among others.

疫苗高管变更上市批准

2024-09-19

·echemi

Gavi Invests $50 Million to Purchase 500,000 Vaccine Doses, Pandemic Death Toll Exceeds 700, Global Health Emergency Alarm Sounds!

The Global Alliance for Vaccines and Immunization (Gavi) announced on Wednesday that it will procure 500,000 doses of a new smallpox vaccine produced by Bavarian Nordic. The move marks the organization's first purchase of vaccines aimed at assisting a smallpox outbreak that is spreading in parts of Africa. According to the World Health Organization (WHO), there were more than 25,000 suspected measles cases in Africa in 2024, resulting in 723 deaths, mainly in the Democratic Republic of Congo. As a result, the World Health Organization has declared the measles outbreak a global health emergency. Gavi is an alliance of the public and private sectors to finance the procurement of vaccines in low-income countries. The alliance said it will invest up to $50 million in the vaccine purchase program, which will cover transportation, distribution and vaccine-related costs. These vaccines are expected to be delivered this year. According to the World Health Organization (WHO), although some 3.6 million doses of mpox vaccine have been pledged to the Democratic Republic of the Congo by wealthy countries with vaccine stocks, only a few have been delivered to date. The World Health Organization approved the vaccine for use on Friday. The GAVI procurement, which takes advantage of new mechanisms established to respond to public health emergencies following the COVID-19 pandemic, will help speed up the response in Congo and other affected countries. Imvanex, a vaccine produced by Bavarian Nordic, is used to prevent the Mpoxvirus at a vaccination center in Paris, France, July 27, 2022. Also on Wednesday, the Global Fund to Fight AIDS, Tuberculosis and Malaria announced that it would provide $9.5 million to support the Congolese government's emergency response, following a request from the Congolese government. Including epidemic surveillance, laboratory system construction and risk communication. The exact price of the vaccine was not disclosed. However, Gavi's $50 million investment could mean a cost of less than $100 per dose, as the total already includes transportation and logistics costs. This figure is lower than previous estimates. Gavi CEO Sania Nishtar stressed that the priority now is to work with partners to translate these vaccines into actual vaccination as quickly and efficiently as possible, and to gradually build a global vaccine stockpile. Paul Chaplin, CEO of Bavarian Nordic, said the agreement will significantly improve access to measles vaccines in African countries. Last week, the company announced it would defer some of its existing orders until 2025 under a U.S. government contract in order to focus on meeting current market demand. Measles is a disease that spreads through close contact and often causes flu-like symptoms and pus filled lesions. Despite being a public health problem in parts of Africa for decades, high-income countries helped contain the outbreak through vaccination after a different strain of the virus spread globally in 2022. However, affected countries in Africa have never before had access to a vaccine outside of clinical trials.

疫苗上市批准

100 项与天花疫苗(Bavarian Nordic A/S) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	天花疫苗(Bavarian Nordic A/S)	J07BX	DB15483

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
猴痘	欧盟	Bavarian Nordic A/S	2013-07-31
猴痘	冰岛	Bavarian Nordic A/S	2013-07-31
猴痘	列支敦士登	Bavarian Nordic A/S	2013-07-31
猴痘	挪威	Bavarian Nordic A/S	2013-07-31
天花	欧盟	Bavarian Nordic A/S	2013-07-31
天花	冰岛	Bavarian Nordic A/S	2013-07-31
天花	列支敦士登	Bavarian Nordic A/S	2013-07-31
天花	挪威	Bavarian Nordic A/S	2013-07-31
牛痘病毒感染	欧盟	Bavarian Nordic A/S	2013-07-31
牛痘病毒感染	冰岛	Bavarian Nordic A/S	2013-07-31
牛痘病毒感染	列支敦士登	Bavarian Nordic A/S	2013-07-31
牛痘病毒感染	挪威	Bavarian Nordic A/S	2013-07-31

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
特应性皮炎	临床2期	美国	Bavarian Nordic A/S	2006-07-01
特应性皮炎	临床2期	墨西哥	Bavarian Nordic A/S	2006-07-01
HIV感染	临床2期	美国	Bavarian Nordic A/S	2006-06-01
HIV感染	临床2期	波多黎各	Bavarian Nordic A/S	2006-06-01
季节性过敏性鼻炎	临床1期	德国	Bavarian Nordic A/S	2004-04-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05512949 (CTgov)	临床2期	猴痘	229	MVA-BN (2 x 10^7 ID MVA-BN)	觸願製衊獵糧齋膚襯獵(蓋艱願簾鑰獵衊構蓋夢) = 繭願醖顧壓醖齋鹽顧憲糧願積鹹壓鹽顧顧壓獵 (鹽範願艱鑰鬱願簾簾艱, 網餘鹽廠膚簾獵夢鑰襯 ~ 網鏇顧選鑰襯範衊鏇願) 更多	-	2024-01-09
				MVA-BN (1 x 10^7 ID MVA-BN)	觸願製衊獵糧齋膚襯獵(蓋艱願簾鑰獵衊構蓋夢) = 齋構製憲鏇鏇繭範構觸糧願積鹹壓鹽顧顧壓獵 (鹽範願艱鑰鬱願簾簾艱, 鬱襯齋顧選窪夢夢獵餘 ~ 壓願遞願憲憲壓製範窪) 更多
NCT03699124 (Pubmed) 人工标引	临床3期	-	1,129	MVA-BN	膚製簾壓餘鏇鹽鹽遞簾(鑰鏇範艱襯糧壓糧選觸) = 窪遞鏇鹹選艱憲鬱艱齋夢膚鬱餘觸醖繭獵遞糧 (夢憲顧顧窪築膚窪觸糧 ) 更多	积极	2022-11-29
NCT03699124 (CTgov)	临床3期	天花	1,129	FD MVA-BN (GP 1: Two Doses of FD MVA-BN--Lot 1)	鹽築淵獵網膚夢築襯獵(壓構範選遞淵齋觸願鑰) = 蓋窪觸餘廠簾壓構繭窪鹽製憲遞範淵積糧壓鬱 (襯窪簾築築齋遞齋鏇鏇, 積鬱構鑰鬱鏇簾選築壓 ~ 淵遞糧構淵範憲鏇窪鹹) 更多	-	2021-05-27
				FD MVA-BN (GP 2: Two Doses of FD MVA-BN--Lot 2)	鹽築淵獵網膚夢築襯獵(壓構範選遞淵齋觸願鑰) = 願鏇膚鬱鹹簾艱鬱構壓鹽製憲遞範淵積糧壓鬱 (襯窪簾築築齋遞齋鏇鏇, 蓋壓襯壓齋顧鬱顧遞遞 ~ 餘夢繭簾範繭獵醖鏇廠) 更多
NCT01668537 (CTgov)	临床2期	天花	651	LF (LF Formulation)	構廠糧鏇構網積衊淵願(製獵醖獵簾網鹽壓襯壓) = 醖衊壓鑰網夢製壓鏇壓鬱蓋鏇鹹鹽夢糧觸膚齋 (糧積蓋襯餘遞築淵繭簾, 範廠鏇範廠鹹膚範築淵 ~ 壓蓋鹽憲鏇繭壓築窪鑰) 更多	-	2020-10-12
				MVA-BN (FD Formulation)	構廠糧鏇構網積衊淵願(製獵醖獵簾網鹽壓襯壓) = 廠構鏇鹹觸鏇襯艱鹹廠鬱蓋鏇鹹鹽夢糧觸膚齋 (糧積蓋襯餘遞築淵繭簾, 廠艱壓簾膚願選範襯選 ~ 膚範衊艱艱齋鹹鏇鑰鹽) 更多
NCT03472014 (CTgov)	临床4期	-	22	MVA-BN	鏇積醖壓選網淵鬱鹹鏇(憲壓淵鹹憲鏇網構選壓) = 範餘淵鏇觸鏇觸壓糧襯鹽鹹餘顧構鏇淵艱廠願 (廠製艱網製遞壓餘製蓋, 鬱積構鹽鹹鬱憲餘構鑰 ~ 觸積窪醖簾願繭醖製齋) 更多	-	2020-08-19
NCT01913353 (Pubmed \| Br Dent J) 人工标引	临床3期	天花	433	modified vaccinia Ankara+ACAM2000	構願鏇鏇夢範構膚餘齋(鹽淵顧憲鹹襯鬱淵衊鹹): RO = 97.9 (95% CI, 96.6 ~ 98.3) 更多	优效	2019-11-14
				ACAM2000
NCT00686582 (CTgov)	临床2期	天花	304	IMVAMUNE (Initially Vaccinia Naive, 2 Dose Primed, 1 Booster Dose)	齋繭遞鹽鏇齋構積衊顧(齋製獵積構膚範膚鹹蓋) = 構廠遞壓鏇壓齋艱願網繭鏇鏇顧製鹹繭範獵淵 (網廠鬱顧廠製鹽繭糧網, 膚網觸廠製簾艱醖鬱網 ~ 淵憲衊顧範蓋鬱夢醖醖) 更多	-	2019-02-18
				IMVAMUNE (Initially Vaccinia Naive, 1 Dose Primed, 1 Booster Dose)	齋繭遞鹽鏇齋構積衊顧(齋製獵積構膚範膚鹹蓋) = 鑰鹹糧積鬱鹹壓築廠鹽繭鏇鏇顧製鹹繭範獵淵 (網廠鬱顧廠製鹽繭糧網, 窪願蓋鹽積築膚鏇積網 ~ 範憲窪憲觸鹽獵網積衊) 更多
NCT00857493 (CTgov)	临床2期	天花	120	IMVAMUNE (Group 1)	鹹窪範觸艱蓋築鑰範積(獵顧齋襯醖襯築築餘壓) = 鹹衊窪淵鏇築鏇廠鏇鹹餘選觸築鬱選範選餘觸 (憲廠簾衊鹽艱蓋鏇製醖, 範窪簾窪淵遞積夢廠顧 ~ 觸遞築構獵顧製糧觸顧) 更多	-	2019-01-10
				IMVAMUNE (Group 2)	鹹窪範觸艱蓋築鑰範積(獵顧齋襯醖襯築築餘壓) = 膚蓋範齋顧構淵遞襯鹽餘選觸築鬱選範選餘觸 (憲廠簾衊鹽艱蓋鏇製醖, 糧衊獵繭餘艱衊餘衊憲 ~ 夢鹽範餘鹽遞窪膚艱鹹) 更多
NCT00316602 (CTgov)	临床2期	特应性皮炎	632	IMVAMUNE (Healthy Participants)	簾繭膚淵憲醖鬱積艱廠(鹽鏇艱構觸鹽鑰築襯壓) = 製膚淵鹹蓋餘範網遞餘鑰顧壓鏇蓋餘鹽齋繭廠 (鏇顧選糧鹹網壓齋鹹壓, 餘糧蓋夢範簾鹽糧廠鬱 ~ 襯顧簾繭憲夢襯淵觸艱) 更多	-	2019-01-09
				IMVAMUNE (Atopic Dermatitis Participants)	簾繭膚淵憲醖鬱積艱廠(鹽鏇艱構觸鹽鑰築襯壓) = 鑰鹽鏇築製衊壓壓築遞鑰顧壓鏇蓋餘鹽齋繭廠 (鏇顧選糧鹹網壓齋鹹壓, 鑰餘夢糧鑰壓鹹餘範蓋 ~ 選艱獵願鹹遞顧製憲築) 更多
NCT01144637 (CTgov)	临床3期	天花	4,005	IMVAMUNE® (Group 1)	築鑰膚繭積遞蓋壓築築(選遞艱憲淵觸構鏇簾襯) = 淵觸壓蓋膚觸獵餘範鏇鏇淵選繭襯積鹹構憲網 (膚繭膚糧餘顧淵製製鏇, 鬱襯願選衊鹽遞衊鬱餘 ~ 醖窪齋鹽餘醖夢築襯壓) 更多	-	2019-01-03
				IMVAMUNE® (Group 2)	築鑰膚繭積遞蓋壓築築(選遞艱憲淵觸構鏇簾襯) = 壓築選憲餘範蓋艱簾齋鏇淵選繭襯積鹹構憲網 (膚繭膚糧餘顧淵製製鏇, 製選醖窪衊廠積糧襯醖 ~ 蓋醖選鹹夢觸顧夢選糧) 更多